PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Pathology and Translational Medicine10.4132/jptm.2018.07.292018525275-282Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung CancerJi Yeon Kim, Woo Jeong Lee, Ha Young Park, Ahrong Kim, Dong Hoon Shin, Chang Hun Leehttp://www.jpatholtm.org/upload/pdf/jptm-2018-07-29.pdf, http://www.jpatholtm.org/journal/view.php?doi=10.4132/jptm.2018.07.29, http://www.jpatholtm.org/upload/pdf/jptm-2018-07-29.pdf
Clinical Lung Cancer10.1016/j.cllc.2021.03.0182021226e817-e819EGFR L718V (+)/T790M (–) as a Mechanism of Resistance in Patients with Metastatic Non–small-cell Lung Cancer with EGFR L858R MutationsLuis E. Raez, Carlos Carracedo, Leylah M. Drusbosky, Michel Velez, Jennifer Carlisle, Thomas Stinchcombehttps://api.elsevier.com/content/article/PII:S1525730421000723?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730421000723?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2017.08.024201711314-17Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutationEric Santoni-Rugiu, Morten Grauslund, Linea C. Melchior, Junia C. Costa, Jens B. Sørensen, Edyta M. Urbanskahttps://api.elsevier.com/content/article/PII:S0169500217304993?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500217304993?httpAccept=text/plain
Lung Cancer10.1016/s0169-5002(20)30167-72020139S61-S62Utility of T790M plasma and tissue biopsy testing in EGFR mutated non-small-cell lung cancer patientsE. Preda, J. Shamash, K. Tarver, S. Ballhttps://api.elsevier.com/content/article/PII:S0169500220301677?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500220301677?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2017.10.009201711468-69Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case reportAnna Chalmers, Leif Jensen, Wallace Akerleyhttps://api.elsevier.com/content/article/PII:S0169500217305482?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500217305482?httpAccept=text/plain
Thoracic Cancer10.1111/1759-7714.13618202011103020-3023Unusual metachronous lung adenocarcinomas harboring EGFR L858R / T790M mutations: A case reportGuotian Pei, Shanbo Cao, Yuqing Huanghttps://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13618, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1759-7714.13618, https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13618
Frontiers in Pharmacology10.3389/fphar.2021.660313202112AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung CancerGeunho Choi, Daegeun Kim, Junehwan Ohhttps://www.frontiersin.org/articles/10.3389/fphar.2021.660313/full
Lung Cancer10.1016/s0169-5002(17)30121-62017103S3471: Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)P.J. Lewis, R.A. Coxhttps://api.elsevier.com/content/article/PII:S0169500217301216?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0169500217301216?httpAccept=text/xml
Lung Cancer10.1016/j.lungcan.2019.10.028202013928-34Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIsMasayuki Takeda, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Koji Haratani, Takayuki Takahama, Ryoji Kato, Kimio Yonesaka, Kazuto Nishio, Kazuhiko Nakagawahttps://api.elsevier.com/content/article/PII:S0169500219307093?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500219307093?httpAccept=text/plain
Clinical Lung Cancer10.1016/j.cllc.2018.08.0012018196e871-e874Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib StudyHiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, Daichi Fujimoto, Akito Hata, Nobuyuki Katakami, Keisuke Tomii, Toshio Shimokawa, Nobuyuki Yamamotohttps://api.elsevier.com/content/article/PII:S1525730418301955?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730418301955?httpAccept=text/plain